electroCore Announces the Commercial Launch of TAC-STIM™
2024年6月25日 - 9:00PM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, is thrilled to announce the
Commercial Off the Shelf (COTS) availability of the next generation
TAC-STIM™, a non-invasive vagus nerve stimulator (nVNS) designed in
partnership with the US military to enhance human performance
exclusively for active-duty military use.
TAC-STIM is a cutting-edge device that can accelerate learning
and improve mood and cognitive performance. TAC-STIM is a portable,
easy-to-use tool that leverages electroCore's patented technology
to deliver precise and effective vagus nerve stimulation, helping
war fighters and operators learn new tasks, increase readiness and
mitigate fatigue across a range of high-pressure operational
environments.
TAC-STIM was originally developed in close collaboration with
the 711th Human Performance Wing at the Air Force Research
Laboratory (AFRL), Wright-Patterson AFB, OH, as part of the United
States Department of Defense Biotech Optimized for Operational
Solutions and Tactics (BOOST) program. Independent testing by AFRL
and Air Force Special Operations Command consistently demonstrated
its capabilities across a range of operational settings.
electroCore continues to participate in collaborative research to
further enhance TAC-STIMs operational utility and showcase how
TAC-STIM can enhance performance, reduce fatigue, and accelerate
training without adverse effects.
Key benefits of TAC-STIM include:
- Improve performance and combat fatigue for 12-24 hours under
extreme conditions
- 20-35% faster learning of complex material
- Enhance ability to multi-task
- Significantly decreased fatigue and increased focus
"TAC-STIM represents a significant advancement in our mission to
support those who serve," said Dan Goldberger, CEO of electroCore.
"By enhancing force readiness, TAC-STIM has the potential to make a
substantial impact on the effectiveness and wellbeing of military
personnel."
TAC-STIM is available for wholesale purchase only. More
information is available at www.TAC-STIM.com, or contacting us by
phone at 888-901-7846 or by email at support@tac-stim.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine
and wellness company dedicated to improving health and promoting
general wellness through its non-invasive vagus nerve stimulation
(“nVNS”) technology platform. The company is focused on the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About TAC-STIM
Proudly made in the USA, TAC-STIM™ is a non-invasive vagus nerve
stimulator (nVNS ) that utilizes the company’s patented technology
to stimulate the vagus nerve. This portable device is designed to
work quickly, and enhances human performance by improving memory
retention, attention, and mood, accelerating training, and
decreasing fatigue. TAC-STIM is a low-risk general wellness product
and is not intended to treat or diagnose any medical condition or
disease.
For more information, visit www.tac-stim.com.
Forward-Looking Statements
This press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects, new and existing wellness and mental acuity product
offerings including the next generation TAC-STIM, commercialization
of the next generation TAC-STIM, new ecommerce site, and clinical
and product development plans; its pipeline or potential markets
for its technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments including focus group study
results; the Company’s business prospects in the United States
(including its e-commerce initiatives) and other new markets and
other statements that are not historical in nature, particularly
those that utilize terminology such as "anticipates," "will,"
"expects," "believes," "intends," other words of similar meaning,
derivations of such words and the use of future dates. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the ability to raise the additional funding needed to
continue to pursue electroCore’s business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, the ability to commercialize gammaCore™,
the ability to successfully launch and commercialize Truvaga Plus
and TAC-STIM, electroCore’s results of operations and financial
performance, and competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/26df7d19-48c7-4e5e-af28-6c5f0e09e581
electroCore (NASDAQ:ECOR)
過去 株価チャート
から 5 2024 まで 6 2024
electroCore (NASDAQ:ECOR)
過去 株価チャート
から 6 2023 まで 6 2024